2-bromoethylamine has been researched along with transforming growth factor beta in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arruda, JA; Au, J; Brecklin, C; Dunea, G; Garber, SL; Mo, W; Pegoraro, AA; Singh, AK; Song, RH | 1 |
| Arruda, JA; Brecklin, CS; Dunea, G; Garber, SL; Grove, BH; Mirochnik, Y; Singh, AK; Slobodskoy, L; Unemori, EN | 1 |
2 other study(ies) available for 2-bromoethylamine and transforming growth factor beta
| Article | Year |
|---|---|
Changes in collagenases and TGF-beta precede structural alterations in a model of chronic renal fibrosis.
Topics: Animals; Chronic Disease; Collagenases; Ethylamines; Fibrosis; Gelatinases; Kidney; Kidney Papillary Necrosis; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tissue Distribution; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta | 1999 |
Relaxin decreases renal interstitial fibrosis and slows progression of renal disease.
Topics: Animals; Creatinine; Disease Progression; Ethylamines; Fibrosis; Kidney; Kidney Cortex; Kidney Diseases; Kidney Medulla; Kidney Tubules; Male; Rats; Rats, Sprague-Dawley; Relaxin; Transforming Growth Factor beta | 2001 |